Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04333745 · ClinicalTrials.gov registry record · NA
Influence of Obesity on Oxalate Metabolism and Handling in Calcium Oxalate Stone Formers
A NA study of Kidney Stone, sponsored by University of Alabama at Birmingham.
- Active
- Registry status
- NA
- Development phase
- 22
- Enrollment target
- 2
- Study locations
NCT04333745: Active NA study of Kidney Stone, sponsored by University of Alabama at Birmingham.
NCT04333745 is a NA study of Kidney Stone that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 22 participants, below the 192-participant average among 28 other Kidney Stone trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04333745, a NA study of Kidney Stone, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary goals of this study are to determine the contribution of dietary oxalate absorption, renal oxalate handling, and endogenous oxalate synthesis to urinary oxalate excretion in normal Body Mass Index (BMI) and obese calcium oxalate kidney stone formers.
Primary Outcome
Urinary oxalate excretion from urine samples will be measured as mg/day
Conditions Studied
Interventions
- OTHER Controlled Diet
- DIETARY_SUPPLEMENT Carbon-13 Oxalate and Sucralose Ingestion
Study Locations (2)
Alabama
- University of Alabama at Birmingham - Birmingham
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2021-09-01 |
| Est. Completion | 2026-12-01 |
| Phase | NA |
What the registry record for NCT04333745 still lists
NCT04333745 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 192-participant average among 28 other Kidney Stone trials with a reported enrollment target (89% lower).
The record links to 1 condition, with Kidney Stone appearing as the primary indexed condition, and to 2 interventions - of which Controlled Diet is the first listed.
NCT04333745 reports a single indexed study location in Alabama, Texas.
Frequently Asked Questions
What is clinical trial NCT04333745 about?
NCT04333745 is a clinical study titled "Influence of Obesity on Oxalate Metabolism and Handling in Calcium Oxalate Stone Formers". The primary goals of this study are to determine the contribution of dietary oxalate absorption, renal oxalate handling, and endogenous oxalate synthesis to urinary oxalate excretion in normal Body Mass Index (BMI) and obese calcium oxalate kidney stone formers.
What is the current status of trial NCT04333745?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 22 participants. The study started on 2021-09-01. Estimated completion is 2026-12-01.
What conditions does trial NCT04333745 study?
This clinical trial studies the following conditions: Kidney Stone.
What interventions are being tested in trial NCT04333745?
The interventions under investigation include: Controlled Diet (OTHER), Carbon-13 Oxalate and Sucralose Ingestion (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04333745?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04333745 being conducted?
This trial has 2 study locations across Alabama, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Stone
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04333745's enrollment target sits among peer trials
22 25th of 28 higher than 4 of 28 other Kidney Stone trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Stone trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Oxalate and Citrate in Humans - Response to Citrate
RECRUITING · NA
-
Gut Oxalate Absorption in Calcium Oxalate Stone Disease
RECRUITING · NA
-
High Powered Stone Dusting vs. Fragmentation and Basketing at Time of Ureteroscopy
RECRUITING · NA
-
Access Sheath and Stent Trial
RECRUITING · NA
-
GI Oxalate Absorption
RECRUITING · NA
-
Evaluation of the LithoVue Elite Ureteroscope With Intra-Renal Pressure Monitoring Technology: Examination of Surgeon Behavior and Post-operative Outcomes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI